In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q4 2007

Executive Summary

We present another installment of our quarterly review of pharmaceutical/biotechnology dealmaking-for October-December 2007. Our data comes from Windhover's Strategic Transactions Database, which covers deal activity within the pharmaceutical/biotechnology, medical device, and in vitro diagnostics and research industries.
Advertisement

Related Content

Start-Up Quarterly Statistics, Q4 2007
Eisai Surprise Winner in MGI Auction
Biopharma VC Exits 2005-2007: Cheap IPOs, Expensive Acquisitions
The A-List: 2007's Trend Shaping Series A Financings
Insulin Delivery: Still Waiting to Exhale
Pharmion's Euro Bet Pays Off
The Drug Delivery Road Gets Tougher
The Eyes Still Have It: Finding Cures For Diseases that Blind Remains Top Focus for Investors, Entrepreneurs
European IPOs Hold Their Own
Specialty Pharma: Tapping Japan

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003068

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel